About Nimbus Therapeutics
Nimbus Therapeutics is a structure-based drug discovery company that develops breakthrough small molecule medicines through AI-enhanced computational chemistry. Founded in 2009 as Nimbus Discovery and evolving into Nimbus Therapeutics in 2015, the company has established a remarkable track record in precision drug design. Nimbus pursues well-validated but difficult-to-drug targets with high potential to transform patients' lives, combining leading-edge computational technologies with machine learning-based predictive modeling approaches. The company's mission centers on developing breakthrough medicines for patients through precision small molecule design, with exquisite selectivity at the core of everything they do. Nimbus has successfully advanced four programs into clinical development and executed transformative partnerships, including a $6 billion sale of its TYK2 program to Takeda and a $1.2 billion sale of its NASH (ACC) program to Gilead, returning over $4 billion to investors. Nimbus's current pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2 clinical development for microsatellite instability high (MSI-H) tumors, a salt-inducible kinase 2 (SIK2) inhibitor program advancing toward first-in-human studies for inflammatory and autoimmune diseases, and multiple preclinical programs in oncology, immunology, and metabolic diseases. The company is headquartered in Boston, Massachusetts, and prides itself on its nimbleness, expertise, focus on collaboration, and rich supportive culture.
Mission & Story
Mission
Our mission is to develop breakthrough medicines for patients through precision small molecule design
Founding Story
Founded in 2009 as Nimbus Discovery, the company evolved into Nimbus Therapeutics in 2015. The name 'Nimbus' signifies a radiant light or luminosity, evoking the image of an aura of excellence, expertise, and achievement, embodying the ideal of illuminating the path from discovery to new medicines through a passionate team, multidisciplinary approach, and pioneering molecules.
Clinical Focus
Medical conditions and clinical areas addressed by Nimbus Therapeutics.
Who It Serves
Milestones & Awards
Recent Milestones
WRN inhibitor NDI-219216 entered Phase 1/2 clinical trial (April 2025), dose escalation completed (December 2025). Research collaboration with Lilly for novel oral obesity treatment announced (January 2026). SIK2 inhibitor program advancing toward first-in-human studies. Abbas Kazimi appointed CEO (March 2025). Secured $210M financing (September 2023).
Awards & Recognition
Ian Sanderson (CFO) recognized by Boston Business Journal as 'Small Company CFO of the Year' in 2019
Key Partnerships
Social & Media
Follow on
Latest Updates
Nimbus Therapeutics Presents First Preclinical Data on Novel WRN Inhibitor NTX-452 at 36th EORTC-NCI-AACR Symposium
Nimbus Therapeutics Achieves Research Milestone in Collaboration with Lilly
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Executive Officer
Company Details
- Founded
- 2009
- Headquarters
- Boston, MA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.